PFIZER, TURNABOUT, AND FAIR PLAY: Pfizer, which played an unfortunate role in the Kelo case, is now finding itself bitten by dubious eminent-domain practices. Ilya Somin cautions that two wrongs don’t make a right — which is true, but on the other hand sometimes they make the practitioner of the first wrong more aware of its wrongness. . . .